ESMO Guidelines Working Group
Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Annals of Oncology 20 (Supplement 4): iv121–iv122, 2009

National Comprehensive Cancer Network (NCCN)
Head and Neck Cancers
NCCN Clinical Practice Guidelines in Oncology . 2010.

Head and neck cancer.National Cancer Institute. 2011
En español.Cancer de cabeza y cuello.

Metastatic Squamous Neck Cancer with Occult Primary. National Cancer Institute. 2009
En español. Cáncer escamoso de cuello con tumor primario oculto metastásico

American College of Radiology
Retreatment of recurrent head and neck cancer after prior definitive radiation.
American College of Radiology  .2010. NGC

American College of Radiology
Neck Mass/Adenopathy
ACR Appropriateness Criteria. 2009. NGC.

The Management of Head and Neck. Cancer in Ontario. 2009

Cetuximab for the treatment of head and neck cancer. Nice. 2008.

Diagnosis and Management of head and neck cancer. Scottish Intercollegiate Guidelines Network (SIGN). 2006. NGC.

Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. National Institute for Health and Clinical Excellence (NICE). 2009. NGC

Head and neck cancer. In: Suspected cancer in primary care: guidelines for investigation, referral and reducing ethnic disparities. New Zealand Guidelines Group. 2009. NGC.

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. National Institute for Health and Clinical Excellence (NICE) 2008. NGC.

The management of head and neck cancer in Ontario: organizational and clinical practice guideline recommendations. Cancer Care Ontario. Program in Evidence-based Care. 2009. NGC.

Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations. Cancer Care Ontario. Program in Evidence-based Care. 2009. NGC.

The role of postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck. Toronto (ON): Cancer Care Ontario (CCO); 2004 (Evidence-based series; no. 5-10). 2004.

Improving outcomes in head and neck cancers. NICE. 2004. The Manual.

Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients. Cancer Care Ontario Practice Guidelines Initiative. 2004.

Concomitant Chemotherapy and Radiotherapy in Squamous Cell Head and Neck Cancer (Excluding Nasopharynx). Cancer Care Ontario.  (Practice Guideline Report No. 5-6a).2002.

Hyperfractionated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Cancer Care Ontario (Practice Guideline Report No. 5-6b). 2003.

Accelerated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Care Ontario (Practice Guideline Report No. 5-6c). 2002.

Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Excluding Nasopharynx) Cancer Care Ontario Practice Guidelines Initiative. 2003.

The role amifostine as a Radioprotectant in the Management of Patients with Squamous Cell Head and Neck Cancer. Cancer Care Ontario.2004. NGC.